The effect of methotrexate-loaded bone cement on local destruction by the VX2 tumour.
Previous studies have shown that the activity of the cytostatic drug methotrexate (MTX) embedded in acrylic cement is not affected by thermal changes in the cement. MTX is slowly released from the cement for several months and remains biologically active throughout this period. Our aim was to determine whether MTX embedded in cement would control the local growth of a tumour. In 15 rabbits we injected 0.1 ml of VX2 tumour suspension into the proximal tibia. At 3, 5, 7, 10 and 14 days three animals were killed and the tibiae removed and examined histologically. With increasing growth of the VX2 carcinoma there was increased bone destruction and a rise in the numbers of osteoclasts, but after 14 days the numbers of osteoclasts had decreased. We then injected VX2 into the tibiae of another 45 rabbits. After 5 days most of the tumour was curetted out and the defect filled with cement containing either 0 g, 0.1 g, 0.5 g, 1.0 g or 2.0 g MTX/40 g cement. The rabbits were divided into three groups and killed at 3, 7 or 10 days after implantation of cement. The number of osteoclasts and the amount of bone destruction were measured in each tibia. In all three groups bone destruction and osteoclast proliferation were markedly decreased with higher doses of MTX, but bone destruction was not eliminated. Our findings show that in the higher doses used, which were not toxic to the animal, MTX-embedded cement may be of value in minimising the amount of tumour-induced osteolysis and may be a useful adjunct in the surgical management of pathological fractures.
Wang
H M
HM
University of Manchester, England.
Crank
S
S
Oliver
G
G
Galasko
C S
CS
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001843:Bone Cements; D001859:Bone Neoplasms / Q000473:pathology / Q000628:therapy*; D008727:Methotrexate / Q000008:administration & dosage*; D020366:Methylmethacrylate; D008768:Methylmethacrylates; D009368:Neoplasm Transplantation; D010010:Osteoclasts / Q000473:pathology; D011817:Rabbits; D013977:Tibia / Q000473:pathology
D000964:Antimetabolites, Antineoplastic; D001843:Bone Cements; D008768:Methylmethacrylates; D020366:Methylmethacrylate; D008727:Methotrexate